Monopar appoints Quan Vu as CFO, replacing Karthik Radhakrishnan

Monopar Therapeutics

Karthik Radhakrishnan's employment terminated Feb 28, 2025; he ceased serving as CFO, principal financial and accounting officer.
Quan Vu appointed CFO, principal accounting and financial officer effective March 3, 2025.
Vu brings over 20 years of experience, most recently as Venture Partner at ZhongMei Capital, previously CFO/COO at Ocugen and 180 Life Sciences.
Vu receives annual salary $350,000, target bonus up to 35% of base salary, and stock options for 25,000 shares vesting over 4 years.
Options granted under Monopar's 2016 Stock Incentive Plan; no related party transactions reported.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Karthik Radhakrishnan

Chief Financial Officer

MNPR · Monopar Therapeutics

Effective: 2025-02-28
Successor: Quan Vu
Filed: March 3, 2025, 6:59 PM ET

On February 28, 2025, Karthik Radhakrishnan’s employment with Monopar Therapeutics Inc. (the “Company” or “Monopar”) terminated.

Appointed

Quan Vu

Chief Financial Officer

MNPR · Monopar Therapeutics

Effective: 2025-03-03
Filed: March 3, 2025, 6:59 PM ET

On February 27, 2025, the Company’s Board of Directors appointed Quan Vu, age 53, to succeed Mr. Radhakrishnan as Monopar’s Chief Financial Officer, principal accounting officer and principal financial officer effective March 3, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Karthik Radhakrishnan was terminated as Chief Financial Officer at Monopar Therapeutics.

Action: terminated
Role: Chief Financial Officer

Exact text from the filing

On February 28, 2025, Karthik Radhakrishnan’s employment with Monopar Therapeutics Inc. (the “Company” or “Monopar”) terminated.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Quan Vu was appointed as Chief Financial Officer at Monopar Therapeutics.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On February 27, 2025, the Company’s Board of Directors appointed Quan Vu, age 53, to succeed Mr. Radhakrishnan as Monopar’s Chief Financial Officer, principal accounting officer and principal financial officer effective March 3, 2025.

View on SEC.gov

Monopar Therapeutics filing history →

Source: SEC EDGAR

accession 0001437749-25-005951

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.